Abstract
Entrectinib is a potent, CNS-active ROS1/TRK/ALK inhibitor, which induces clinically meaningful responses in pts with ROS1 fusion-positive (ROS1+) NSCLC and NTRK fusion-positive (NTRK+) solid tumours. We conducted an exploratory analysis to determine if number of prior lines of systemic therapy had any impact on response to entrectinib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
